Literature DB >> 6326007

Oxy-radical toxicity in catecholamine neurons.

G Cohen.   

Abstract

This article summarizes the evidence that oxy-radicals are involved in the destruction of catecholamine neurons by polyphenolic neurotoxins. Superoxide-mediated damage by 6-hydroxydopamine can be suppressed by intracellular catecholamines, which act as scavengers of the superoxide radical. Administration of exogenous hydroxyl radical-scavenging agents protects peripheral sympathetic neurons from destruction by 6-hydroxydopamine, 6- aminodopamine or 5,7-dihydroxytryptamine. Intraneuronal monoamine oxidase may drive cellular senescence of the nigrostriatal tract in patients with Parkinson's disease by generating hydrogen peroxide and derived oxy-radicals during the metabolism of endogenous dopamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326007

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  37 in total

Review 1.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

Review 2.  The expanding role of oxygen free radicals in clinical medicine.

Authors:  M A Katz
Journal:  West J Med       Date:  1986-04

Review 3.  Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia.

Authors:  D G Kirch; A M Alho; R J Wyatt
Journal:  Cell Mol Neurobiol       Date:  1988-09       Impact factor: 5.046

4.  Human aging brain disorders: role of antioxidant enzymes.

Authors:  M R de la Torre; A Casado; M E López-Fernández; D Carrascosa; M C Casado; D Venarucci; V Venarucci
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

5.  2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.

Authors:  P A Rosenberg; R Loring; Y Xie; V Zaleskas; E Aizenman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 6.  Dopamine in gastrointestinal disease.

Authors:  G B Glavin; S Szabo
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

Review 7.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

8.  Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview.

Authors:  D Metodiewa; C Kośka
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

9.  Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease.

Authors:  Renata Pietsch Ribeiro; Eduardo Luiz Gasnhar Moreira; Danúbia Bonfanti Santos; Dirleise Colle; Alessandra Antunes Dos Santos; Kaite Cristiane Peres; Claudia Pinto Figueiredo; Marcelo Farina
Journal:  Neurochem Res       Date:  2013-01-19       Impact factor: 3.996

10.  Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.

Authors:  H Przuntek; D Welzel; E Blümner; W Danielczyk; H Letzel; H J Kaiser; P H Kraus; P Riederer; D Schwarzmann; H Wolf
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.